Stock is trading up ~20% today with Bloomberg reporting that Novartis (NVS) executives suggested at a meeting last night that it and partner MNTA are optimistic US regulators will clear their version of Sanofi's (SNY) Lovenox anti-clot medicine, Mirabaud. "Prospects of a generic Lovenox sometime in late 2008 are more encouraging than they were." In November, the FDA rejected MNTA's bid for approval of the drug M-Enoxaparin... We also note that MNTA was upgraded to Outperform from Underperform at Bear Sterns this morning.